Center Laboratories Inc (CenterLab: 4123.TWO), a Taiwan-based-pharmaceutical company, has met its primary endpoint in a phase two clinical trial of anti-diabetic drug, CS02, it was reported on Friday.

The top-line results of the product's phase two clinical trial revealed a significant decrease of glycated haemoglobin in treated patients compared to the placebo group by 0.45% (p value = 0.0098).

The product is an orally administered small molecule drug under development following the abbreviated 505(b)(2) regulatory pathway for new drug approval. For further development of CS02, CenterLab is actively seeking global partners for co-development or licensing opportunities.